Treatment Found Safe for Nail, Palmoplantar Psoriasis

PsA hand psoriasis Cosentyx (secukinumab) use provides sustained improvements in nail and palmoplantar psoriasis for up to 2.5 years, according to long-term study data reported by Novartis. Until now, no other treatments for these hard-to-treat forms of psoriasis have demonstrated sustained efficacy for as long as 2.5 years.


These findings were recently presented at the 8th International Congress of Psoriasis from Gene to Clinic in London.

In the GESTURE trial, researchers evaluated the efficacy of long-term use of 150 mg and 300 mg Cosentyx in patients with palmoplantar psoriasis. Results of the trial indicated that approximately 53% of patients on 150 mg Cosentyx and 59% of patients on 300 mg Cosentyx had achieved clear or almost clear palms and soles at 2.5 years.

Additionally, in the TRANSFIGURE study, researchers assessed long-term Cosentyx use in patients with nail psoriasis. Similarly, participants were treated with either 150 mg or 300 mg Cosentyx. Results showed that patients on 150 mg Cosentyx had shown a significant improvement in Nail Psoriasis Severity Index (NAPSI) scores from baseline of -73%, and those on 300 mg Cosentyx had shown an improvement from baseline of -63%.

Ultimately, both trials found that Consentyx had a favorable safety profile and was consistently effective for up to 2.5 years.

—Christina Vogt